Safety of Acid-Suppressive Medications During Pregnancy

A recent observational study published in JAMA Network Open highlights the safety of acid-suppressive medications during pregnancy. The research, involving over 2.6 million mother-child pairs from South Korea, found no significant increase in the risk of pediatric inflammatory bowel disease (IBD), Crohn's disease, or ulcerative colitis. Children exposed to proton pump inhibitors (PPI) or H2 receptor antagonists (H2RA) in utero showed no elevated risk compared to those unexposed.

After controlling for confounding variables, the study confirmed the minimal absolute risk of gastrointestinal conditions. A sibling pair analysis further validated these findings, emphasizing the low risk associated with these medications during pregnancy. Dr. Kara Rood, a maternal-fetal medicine physician, highlighted the reassuring nature of these results, which excluded over-the-counter H2RAs to focus on prescription use in about 18% of the children studied.

Guideline Approaches in Pregnancy Treatment

In the absence of specific guidelines from the American College of Obstetricians and Gynecologists, clinicians typically recommend a step-up approach for heartburn or gastroesophageal reflux during pregnancy. This involves lifestyle modifications and first-line antacids, progressing to H2RAs like Pepcid if necessary, and considering PPIs for severe cases due to their potential impact on nutrient absorption with long-term use.

Dr. Laura Goetzl, a maternal-fetal medicine expert, reinforced the study's outcomes by noting no pathophysiological link between acid-suppressive drugs and autoimmune or gastrointestinal disorders in fetuses. Both Dr. Rood and Dr. Goetzl stressed the importance of managing pregnancy-related symptoms effectively, noting the availability of safe treatment options to prevent discomfort. No conflicts of interest were reported by either physician concerning this study.